BRIEF—Merck KGaA investing 300 million euros in research center

German pharma and life science company Merck KGaA today revealed it is investing more than 300 million euros ($320 million) in a new research center at its global headquarters in Darmstadt, Germany.

In the Advanced Research Center, the Life Science business sector will research solutions for manufacturing antibodies, mRNA applications and additional products required for biotechnological production, among other things.

As of the start of 2027, it will provide space for around 550 employees.

Today, Merck laid the cornerstone for the building together with German Federal Chancellor Olaf Scholz. The new building is part of an investment program in the Darmstadt site: Merck will invest around 1.5 billion euros in total by 2025.

The Darmstadt site is one of the most important Merck centers for R&D in life science technologies.

In the next 10 years, around one fifth of the Life Science business sector’s sales with new products are estimated to come from here.

Since 2020, Merck has announced investments of more than 2 billion euros in the business sector globally.